Introduction: Genetic testing for congenital long QT syndrome (LQTS) has become common.
INTRODUCTION
The congenital long QT syndrome (LQTS) is a genetic arrhythmia syndrome characterized by delayed repolarization, manifest as a prolonged QTc on electrocardiogram, torsades de pointes, and sudden cardiac arrest. The prevalence of LQTS is estimated at 1 per 2,500 persons of European and other ancestries. 1, 2 There are 15 defined subtypes of the LQTS, but the vast majority of genetically confirmed LQTS is explained by mutations in three genes, KCNQ1, KCNH2, and SCN5A. 3 Beta-blockers are the primary therapy for LQTS with sodium channel blockers sometimes used in patients with SCN5A mutations. Approximately 72% of those with high probability of LQTS carry a mutation in a known LQTS gene, 4 including pathogenic variants identified in genes associated with cardiac potassium and sodium channels.
Recent studies have expanded the type of genes associated with LQTS to nonchannel proteins, 5, 6 increasing the catalog of potential susceptibility genes to over 30. 7 Clinical genetic testing for the LQTS has become common with the goal of confirming disease, refining treatment strategies, and facilitating cascade screening to identify at-risk relatives. Several commercial companies currently offer gene panel testing that evaluates pathogenic variants in 12 to 17 LQTS-associated genes. 8, 9 Pathogenic variants of genetic diseases have historically been determined by their presence in one or more clinical cases and their absence in healthy populations. However, assessing the rarity of a variant in a control population has been constrained by the relatively limited number of available sequenced genomes. The recent release of data from the Exome Aggregation Consortium (ExAC) and Genome Aggregation Database (gnomAD), including 60,706 and 123,136 exome sequences from unrelated individuals, respectively, has allowed for a deeper understanding of genetic diversity within the general population. 10, 11 With the much improved catalog of exomewide variation, ExAC has demonstrated that rare genetic variation is, collectively, not so rare in the general population. Thus, this type of collective database can serve as a powerful filter to rule out candidate pathogenic variants in Mendelian disease. 10, 11 The recent American College of Medical Genetics and Genomics guidelines for interpretation of sequence variants state that an allele frequency (AF) for a candidate variant in a control population, such as ExAC and gnomAD, that is greater than expected for the disorder is strong evidence for a benign interpretation. 12 Studies in cardiomyopathy 13 and catecholaminergic polymorphic ventricular tachycardia 14 have shown that some variants labelled as pathogenic might be misclassified due, in part, to relatively common AF in the ExAC population.
Re-evaluating the pathogenicity of LQTS variants is critical since genetic testing results increasingly guide treatment options and screening decisions, and false positive results might have adverse clinical implications. Therefore, the purpose of this study is to examine the presence of LQTS-associated genetic variants in the gnomAD population, and assess the impact of these variants in different functional domains in the most commonly mutated genes, KCNQ1, KCNH2, and SCN5A. 
METHODS

Variant identification
Defining AF threshold
Allele counts (AC) and population-based AF were determined for each variant from the combined gnomAD cohort across all ethnic groups.
We selected AF thresholds of 0.001 and 0.0001 to define potentially pathogenic variants for LQTS since a variant with an AF greater than these thresholds would be too common in the population to be a highly penetrant, monogenic cause of disease. An AF of 0.001 is well established as a rare variant threshold. 10 The AF of 0.0001 is estimated by the method proposed by Walsh et al. 13 and the LQTS prevalence of 1 in 2,500 in the general population. 1 
Clinical cohort
An aggregated clinical cohort of 2,683 LQTS patients was synthetically assembled from the results of eight published studies (Table S2) .
Only studies that provided AC for all variants identified were included.
Three studies sequenced three genes (KCNQ1, KCNH2, SCN5A) [17] [18] [19] and four studies sequenced five genes (KCNQ1, KCNH2, SCN5A, 
Functional domain mapping
Variants identified in the gnomAD and clinical cohorts were mapped to functional protein domains based on the designated amino acid ranges in the three most commonly mutated LQTS genes, KCNQ1, KCNH2, and SCN5A (Table S3) equal to 75% and were considered pathogenic (Table S3 ).
Statistical analysis
Fisher's exact and chi-square tests were applied to compare LQTS variants in different subgroups. A two-sided P value of < 0.05 was considered significant for comparisons of pathogenicity for groups of variants based on MetaSVM prediction. For protein topology analysis, allele distribution by functional domain was compared between gnomAD and clinical cohorts. A Bonferroni-adjusted P value of < 3.85E-03 was used for significance.
RESULTS
From HGMD, 1,415 single nucleotide, disease-causing, or likely disease-causing variants were identified from 31 genes (Table 1 ). After quality filtering and position/allele matching, 347 of the 1,415 (25%)
variants from 22 genes were identified in gnomAD, including 303 disease-causing and 44 likely disease-causing variants ( Table 2 ). The ensemble algorithm MetaSVM predicted that 24% of the 347 LQTS variants present in gnomAD would be functionally tolerated, compared with 4% of variants not present in gnomAD (P < 0.001, Table 2 ).
These 347 variants were found in 9,525 individuals of the gnomAD cohort representing 9,652 alleles (9,398 individuals were heterozygotes and 127 individuals were homozygous for the variant). The average number of alleles sequenced per these LQTS variants was 236,063, or 118,031 individuals of the gnomAD cohort. Assuming that each variant is pathogenic and an individual only carries 1 variant, the calculated prevalence of LQTS in the gnomAD cohort would be 1 in 12.4. Using the previously reported LQTS prevalence of 1 in 2,500 in the general population, the expected number of LQTS cases in gnomAD would be 47.
Among the 347 pathogenic variants in gnomAD, seven (2%) had an AF of ≥ 0.001 and 65 (19%) variants had an AF of ≥0.0001 (Table S4) . MetaSVM predicted that 39% of the 65 LQTS variants with AF > 0.0001 would be tolerated compared with 20% of variants with AF < 0.0001 (P = 0.001, Table 2 ). Literature review demonstrated that pathogenicity of the 65 variants with AF ≥ 0.0001 was initially based on comparison to 100 to 3,000 control alleles and only five (7%) demonstrated segregation in family-based studies (Table S4) . Only nine variants (13%) had experimental data investigating their effects on ion channel function. Of these, one variant (KCNE3 p.T4A) had no significant effect on channel function, two variants (SCN5A p.S1904L; KCNE1 p.V109I) had modest effects on channel function, and the remainder had significant functional effects (Table S4 ).
To examine the variant distribution in the LQTS patient population, we synthetically aggregated a clinical cohort from eight published studies. In a total of 2,683 subjects from this clinical cohort, 1,950 pathogenic alleles were identified in 1,647 subjects. We limited our analysis to the 1,430 alleles that matched to the 1,415 single nucleotide variants identified from HGMD, which includes 580 variants from 10 genes ( Table 1 ). The majority (96%) of these 580 variants were predicted as deleterious by MetaSVM, while 128 (22%) Variants in other genes* includes ANK2 (n = 3), CACNA1 (n = 1), CAV3 (n = 1), KCNE1 (n = 9), KCNE2 (n = 2), KCNJ2 (n = 2), and SCN4B (n = 1) of them were also detected in the gnomAD cohort with a wide range of AF in both datasets (Fig. 1) . All sequenced alleles in KCNQ1, KCNH2, and SCN5A genes from gnomAD and the clinical cohort were mapped to the protein function regions. Allele distribution by functional domain was significantly different between gnomAD and the clinical cohort (Table 3 ). In six of seven pathogenic domains, gnomAD alleles appeared less frequently than clinical cohort alleles, meeting Bonferroni corrected significance level (P < 0.0038) in five of these pathogenic domains (Table 3 ). There were 45 variants in KCNQ1, KCNH2, and SCN5A that had an AF > 0.0001 in gnomAD. Of these, 18 (40%) mapped to the pathogenic domains. An additional comparison between the gnomAD and clinical cohorts shows that deleterious variants in KCNQ1, KCNH2, and SCN5A as predicted by MetaSVM are more prevalent in the clinical cohort than in gnomAD (P < 0.001; Table S5 ).
DISCUSSION
This study demonstrates that a significant number of variants asso- (n = 7,030 subjects), respectively. 27, 28 The findings from this study extend the prior work in important ways. Compared to ESP, the sample size of gnomAD provided greater power to filter rare variants. 10, 11 More variants overall were identified in gnomAD than in ESP, and a higher percentage of these variants were identified in more than one individual. We also used two methods to
show that many of the LQTS-associated variants in gnomAD, especially those with higher AF, are expected to result in nonpathogenic effects.
One method involved the support vector machine (SVM) based ensemble prediction score which incorporated ten commonly-used annotation tools and the AF information from the 1,000 Genomes Project to evaluate the functionality of genetic variants. 16 The other leveraged the work of Ackerman et al., who identified pathogenic topological regions in the three most commonly mutated LQTS genes. 17, 25 They reported that variants within these functional regions were more likely to be associated with true disease. By mapping the variants from gnomAD onto these functional domains, we were able to show that the gnomAD alleles were less likely to be located in one of the pathogenic regions. Additionally, we confirmed that many of the variants with an AF above 0.0001 have insufficient evidence (small control groups, lack of functional or segregation data) to support the designation of pathogenicity.
It is important to explain two apparent paradoxes in the results of the study. In particular, eight variants had functional data supporting a pathogenic effect of the variant but were also found at high allele frequency within the general population of gnomAD. Also, 75% of LQTSassociated variants found in gnomAD were predicted to be damaging 
LIMITATIONS
This study is limited by the lack of phenotyping of the gnomAD cohort.
It is possible that there may be some over-representation of LQTS within gnomAD. It is also possible that some pathogenic variants are present in gnomAD due to variable penetrance of the disease, subclinical disease, or normalizing effects of disease modifying variants. It is unlikely, however, that these possibilities would account for more than just a few of the more than 9,600 alleles identified. Due to the limited sample size and ethnic diversity of our aggregated clinical cohort (Table S2) , we used the combined gnomAD samples and did not explore the AF distribution by ethnic groups. The estimation and classification of pathogenic variants could present differently in individuals with different genetic background. Another limitation is that the clinical cohort may include nondiseased patients. While we focused on studies that enrolled clinically diagnosed patients, we did include one study that reported clinical genetic testing results. 24 This study was included because it included phenotype data and that data suggested that patients with positive genetic tests were more likely to have phenotypic features of the LQTS.
CONCLUSION
A significant number of LQTS-associated variants labelled as disease causing have an AF inconsistent with a rare disease, have amino acid changes that are predicted to be tolerated, and have insufficient evidence for pathogenicity. Caution should be used when ascribing disease causation to these variants.
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